Vasculitis: Molecular imaging by targeting the inflammatory enzyme myeloperoxidase

Radiology

Volumn 262, Issue 1, 2012, Pages 181-190

  Su, Henry S ^a   Nahrendorf, Matthias ^a   Panizzi, Peter ^a   Breckwoldt, Michael O ^a,b   Rodriguez, Elisenda ^a   Iwamoto, Yoshiko ^a   Aikawa, Elena ^a   Weissleder, Ralph ^a   Chen, John W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; GADOLINIUM PENTETATE BIS 5 HYDROXYTRYPTAMIDE; GADOLINIUM PENTETATE MEGLUMINE; MYELOPEROXIDASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; BONE MARROW CELL; CANDIDA ALBICANS; CHEMICAL ANALYSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; IMAGE ANALYSIS; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TARGETING; SHAM PROCEDURE; SIGNAL NOISE RATIO; VASCULITIS;

ANIMALS; AORTA; CELL MOVEMENT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRAST MEDIA; GADOLINIUM DTPA; IMMUNOHISTOCHEMISTRY; MICE; MOLECULAR IMAGING; MUCOCUTANEOUS LYMPH NODE SYNDROME; PEROXIDASE; RANDOM ALLOCATION; STATISTICS, NONPARAMETRIC;

EID: 84455200779     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11110040     Document Type: Article

References (41)

1. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68(3):310-317.
2. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68(3):318-323.
3. Imboden JB, Hellmann DB, Stone JH. Current rheumatology: diagnosis & treatment. New York, NY: Lange Medical Books/McGraw-Hill, Medical Pub. Division, 2004.
4. Jennette JC, Falk RJ. Nosology of primary vasculitis. Curr Opin Rheumatol 2007;19(1):10-16. (Pubitemid 44885721)
5. Chen M, Kallenberg CG. ANCA-associated vasculitides: advances in pathogenesis and treatment. Nat Rev Rheumatol 2010;6(11):653-664.
6. Kallenberg CG, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006;2(12):661-670. (Pubitemid 44830855)
7. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349(17):1595- 1604. (Pubitemid 37288567)
8. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005;25(6):1102-1111. (Pubitemid 40776595)
9. Rutgers A, Heeringa P, Tervaert JW. The role of myeloperoxidase in the pathogenesis of systemic vasculitis. Clin Exp Rheumatol 2003;21(6 suppl 32):S55-S63. (Pubitemid 38016480)
10. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110(7):955-963.
11. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006;368(9533):404-418. (Pubitemid 44108124)
12. Falcini F. Kawasaki disease. Curr Opin Rheumatol 2006;18(1):33-38. (Pubitemid 43740403)
13. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110(17):2747-2771. (Pubitemid 39453026)
14. Murata H. Experimental candida-induced arteritis in mice: relation to arteritis in the mucocutaneous lymph node syndrome. Microbiol Immunol 1979;23(9):825-831. (Pubitemid 10244056)
15. Takahashi K, Oharaseki T, Wakayama M, Yokouchi Y, Naoe S, Murata H. Histopathological features of murine systemic vasculitis caused by Candida albicans extract: an animal model of Kawasaki disease. Inflamm Res 2004;53(2):72-77. (Pubitemid 38223372)
16. Nagi-Miura N, Harada T, Shinohara H, et al. Lethal and severe coronary arteritis in DBA/2 mice induced by fungal pathogen, CAWS, Candida albicans water-soluble fraction. Atherosclerosis 2006;186(2):310-320.
17. Geiger J, Ness T, Uhl M, et al. Involvement of the ophthalmic artery in giant cell arteritis visualized by 3T MRI. Rheumatology (Oxford) 2009;48(5):537-541.
18. Küker W, Gaertner S, Nagele T, et al. Vessel wall contrast enhancement: a diagnostic sign of cerebral vasculitis. Cerebrovasc Dis 2008;26(1):23-29. (Pubitemid 351931417)
19. Markl M, Uhl M, Wieben O, et al. High resolution 3T MRI for the assessment of cervical and superficial cranial arteries in giant cell arteritis. J Magn Reson Imaging 2006;24(2):423-427. (Pubitemid 44188571)
20. Querol M, Chen JW, Weissleder R, Bogdanov A Jr. DTPA-bisamide-based MR sensor agents for peroxidase imaging. Org Lett 2005;7(9):1719-1722. (Pubitemid 40685347)
21. Chen JW, Querol Sans M, Bogdanov A Jr, Weissleder R. Imaging of myeloperoxidase in mice by using novel amplifiable paramagnetic substrates. Radiology 2006;240(2):473-481. (Pubitemid 44098644)
22. Uchiyama M, Ohno N, Miura NN, et al. Chemical and immunochemical characterization of limulus factor G-activating substance of Candida spp. FEMS Immunol Med Microbiol 1999;24(4):411-420. (Pubitemid 29313320)
23. Chen JW, Breckwoldt MO, Aikawa E, Chiang G, Weissleder R. Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain 2008;131(Pt 4):1123-1133. (Pubitemid 351499418)
24. Powell DH, Ni Dhubhghaill OM, Pubanz D, et al. Structural and dynamic parameters obtained from 17O NMR, EPR, and NMRD studies of monomeric and dimeric Gd3+ complexes of interest in magnetic resonance imaging: an integrated and theoretically self-consistent approach. J Am Chem Soc 1996;118(39):9333-9346. (Pubitemid 26355128)
25. Bui T, Stevenson J, Hoekman J, Zhang S, Maravilla K, Ho RJ. Novel Gd nanoparticles enhance vascular contrast for high-resolution magnetic resonance imaging. PLoS ONE 2010;5(9):pii: e13082.
26. Rodríguez E, Nilges M, Weissleder R, Chen JW. Activatable magnetic resonance imaging agents for myeloperoxidase sensing: mechanism of activation, stability, and toxicity. J Am Chem Soc 2010;132(1):168-177.
27. Breckwoldt MO, Chen JW, Stangenberg L, et al. Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc Natl Acad Sci U S A 2008;105(47):18584-18589.
28. Nahrendorf M, Sosnovik D, Chen JW, et al. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 2008;117(9):1153-1160. (Pubitemid 351552019)
29. Ronald JA, Chen JW, Chen Y, et al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active infl ammation in experimental rabbit atherosclerotic plaques. Circulation 2009;120(7):592-599.
30. Swirski FK, Wildgruber M, Ueno T, et al. Myeloperoxidase-rich Ly-6C+ myeloid cells infiltrate allografts and contribute to an imaging signature of organ rejection in mice. J Clin Invest 2010;120(7):2627-2634.
31. van Duijnhoven SM, Robillard MS, Nicolay K, Grüll H. Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation. J Nucl Med 2011;52(2):279-286.
32. Walter MA. [(18)F]fluorodeoxyglucose PET in large vessel vasculitis. Radiol Clin North Am 2007;45(4):735-744, viii. (Pubitemid 47238397)
33. Sigovan M, Boussel L, Sulaiman A, et al. Rapid-clearance iron nanoparticles for inflammation imaging of atherosclerotic plaque: initial experience in animal model. Radiology 2009;252(2):401-409.
34. Hyafil F, Laissy JP, Mazighi M, et al. Ferumoxtran-10-enhanced MRI of the hypercholesterolemic rabbit aorta: relationship between signal loss and macrophage infiltration. Arterioscler Thromb Vasc Biol 2006;26(1):176-181. (Pubitemid 43732246)
35. Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008;117(3):379-387.
36. Anderson CF, Mosser DM. A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol 2002;72(1):101-106.
37. Sunderkötter C, Nikolic T, Dillon MJ, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004;172(7):4410-4417. (Pubitemid 38375256)
38. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5(12):953-964. (Pubitemid 41746764)
39. Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007;204(12):3037-3047. (Pubitemid 350179569)
40. Helm PA, Caravan P, French BA, et al. Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology 2008;247(3):788-796.
41. Ishida-Okawara A, Oharaseki T, Takahashi K, et al. Contribution of myeloperoxidase to coronary artery vasculitis associated with MPO-ANCA production. Inflammation 2001;25(6):381-387. (Pubitemid 33139698)